Ebermin - instructions for use, reviews, analogs and forms of release (ointment 30 g and 200 g Eber Biotech Cuba, gel, cream) for the treatment of trophic ulcers, pressure sores and burns in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Ebermin. Presented are the opinions of visitors to the site - consumers of this medication, as well as the opinions of doctors of specialists on the use of Ebermin produced by Eber Biotech Cuba in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Ebermin with existing structural analogues.Use for the treatment of trophic ulcers, pressure sores and burns in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Ebermin - has a complex wound healing and bactericidal action. The epidermal growth factor human recombinant (rchEhFR, the active substance of the drug Ebermin) stimulates the migration and proliferation of fibroblasts, keratinocytes, endothelial and other cells actively involved in wound healing, promoting epithelization, scarring and restoration of tissue elasticity.

Sulfadiazine silver has a broad spectrum of antimicrobial action; it is active against Gram-positive and Gram-negative bacteria, Candida fungi and dermatophytes.

Epidermal growth factor human recombinant (rchEhFR) is a highly purified peptide. It is produced by the strain of yeast Saccharomyces Cerevisiae, into the genome of which the gene of human epidermal growth factor was introduced into the genome by genetic engineering methods. The rchEhFR, obtained on the basis of recombinant DNA technology, is identical in its mechanism of action to the endogenous epidermal growth factor produced in the body.

The hydrophilic base of the ointment provides a moderate dehydrating effect, reduces pain, creates and maintains the necessary therapeutic concentrations of the active substances in the lesion site. Ebermin has a cosmetic effect, provides aesthetics of the rumen due to the normalization of the orientation and maturation of collagen fibers, preventing pathological scarring.

Composition

Epidermal growth factor human recombinant + Sulfadiazine silver + auxiliary substances.

Pharmacokinetics

When applying the drug to intact skin and burn wound surface reabsorption rCHEF from the place of application in the systemic circulation is not observed.

Indications

The drug is used in adults and children over 1 year for treatment:

• surface and deep skin burns of various degrees;
• trophic ulcers (including chronic venous insufficiency, obliterating endarteritis, diabetes, erysipelas);
• decubitus;
• long-term non-healing wounds (including wounds of the stump, wounds during autodermoplasty in lysis sites and between surviving autolocuts of the skin, as well as residual wounds at donor sites);
• varicose veins of the lower extremities with ulcer and inflammation;
• violations of the integrity of the skin in injuries, surgical and cosmetological interventions;
• frostbite;
• ulcers developing with the administration of cytostatics;
• treatment and prevention of radiation (radiation) dermatitis (including in the conduct of surface radiotherapy).

Forms of release

Ointment for external use 30 g and 200 g (sometimes mistakenly called a gel or cream).

Instructions for use and how to use them

Ebermin can be used at all stages of the wound process.

Preliminary, the standard surgical treatment of the wound is carried out using antiseptic solutions in case of infection. After drying on the wound surface, a layer of ointment is applied about 1-2 mm. When the treatment method is closed, sterile gauze napkins or occlusive film coatings (healing in a moist environment) are placed on top. In a number of cases, for example, for superficial shallow (1-2 degrees) and partially deep (grade 3) burns, it is possible to use an ointment with atraumatic reticular wound covers.

With a moist method of healing, as well as pronounced exudation, it is recommended to apply the ointment once a day.With moderate or poor exudation, the application of the ointment can be performed once every 2 days. In case of adhesion of the bandage to the wound and to prevent unwanted drying of the wound surface, it is recommended to moisten the napkin applied over the ointment with a sterile 0.9% solution of sodium chloride or solutions of antiseptics. With an open (non-detached) method of treatment, the ointment is applied 1-3 times a day.

Toilet wounds before repeated applications of the ointment are carried out using a sterile 0.9% solution of sodium chloride or solutions of antiseptics. The procedure is carried out neatly, avoiding traumatization of the resulting granulation tissue and growing epithelium when removing residual ointments.

Treatment continues until the epithelization of the wound or its readiness for plastic closure with a skin flap.

To prevent radiation dermatitis, an ointment with a layer of 1 mm is applied to the irradiated area of ​​the skin without removing it from the application site within 6-8 hours after irradiation. The use of the ointment is continued daily throughout the course of radiotherapy and does not interrupt any of the irradiation procedures in the event of a forced miss.

Side effect

The drug is well tolerated. In rare cases, development is possible:

• allergic reactions, characteristic for sulfanilamide preparations and preparations containing silver;
• the appearance of burning sensation, pain, constriction and discomfort in the area of ​​application of the ointment (usually pass on their own 5-10 minutes after the dressing is applied).

Contraindications

• children under 1 year;
• hypersensitivity to sulfonamides, silver and other components of the drug.

The drug should not be used on areas with active tumor lesions and for stimulation of scarring in the areas of surgical excision of tumors.

Application in pregnancy and lactation

Ebermin has not been sufficiently studied with regard to the effects on the fetus or infants, so its use is not recommended during pregnancy and during lactation. In the event that a pregnant woman or a breast-feeding woman has a lesion that can be treated with Ebermin, the doctor must determine the risk-benefit ratio and decide on its use.

Use in children

Contraindicated in children under 1 year.

special instructions

Use with caution in congenital deficiency of glucose-6-phosphate dehydrogenase, insufficiency of liver and kidney function.

With an open (non-detached) method of treatment, direct sunlight exposure to the ointment area should be avoided.

Drug Interactions

Incompatibilities or interactions with other drugs have not been noted.

Analogues of the drug Ebermin

Structural analogues of the active ingredient Ebermin does not have a medicine. The drug is unique in the combination of active ingredients that make up the composition.

Analogues for the pharmacological group (regenerants and reparants):

• Adelon;
• Actovegin;
• Apilak;
• Aurobin;
• Balarpan;
• Shostakovskiy's balm;
• Balian;
• Bezornil;
• Bepanten;
• Bepanten plus;
• Betacarotene;
• Betamecil;
• Vinylin;
• Vitanorm;
• Gebreolone;
• Hepatrombin;
• Hyposol;
• Humisol;
• D Panthenol;
• Dalargin;
• Dexpanthenol;
• Depanthol;
• Intragel;
• Kontraktubeks;
• Curious;
• Methyluracil;
• Sodium deoxyribonucleate;
• Panthenol;
• Pantoderm;
• Pentoxyl;
• Piolizin;
• Polyvinox;
• Relief;
• Reparff;
• Retinalamine;
• Rumalon;
• Synovial;
• Solcoseryl;
• Stellanin;
• Stisamet;
• Strix;
• Tyqveol;
• Fitostimulin;
• Fusimet;
• Ebermin;
• Eplan.

Similar medicines:

Other medicines: